The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.

Cancer Manag Res · 2021 · PMC8554313 · PMID 34729023

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might be significantno p-value reported

The present study found that an increased REC and decreased NER at three weeks after pembrolizumab were independently associated with a significantly longer OS and might be significant predictive markers of improved clinical outcomes in patients with advanced UC receiving pembrolizumab.

also in 2,435 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.